Vitaspring Biomedical Co. Ltd. (VSBC) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
Vitaspring Biomedical Co. Ltd. (VSBC) stock forecast summary
Our AI ranks Vitaspring Biomedical Co. Ltd. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Vitaspring Biomedical Co. Ltd. is a small-cap company with a market capitalization of $7M. It ranks number 11 by market capitalization among the 12 Services-Commercial Physical & Biological Research issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for VSBC is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.2%, buy ≥ +0.5%, sell < -0.6%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, VSBC included.
Follow VSBC freeVSBC price chart and AI forecast
How VSBC ranks among 4004 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Vitaspring Biomedical Co. Ltd. (VSBC) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.
Valuation & Market
| Metric | VSBC | Rank |
|---|---|---|
| Market Cap | $7M | 11/12 |
Profitability & Margins
| Metric | VSBC | Rank |
|---|---|---|
| ROA | -5834.5% | 12/13 |
| ROIC | -8.4% | 9/12 |
| Tax Rate | -58.2% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | VSBC | Rank |
|---|---|---|
| Current Ratio | 0.01x | 14/16 |
| Working Capital | -$2M | 10/15 |
Cash Flow
| Metric | VSBC | Rank |
|---|---|---|
| Operating Cash Flow | $90K | 6/15 |
Operational Efficiency
| Metric | VSBC | Rank |
|---|---|---|
| Payables Period | 0 days | 6/6 |
Income Statement
| Metric | VSBC | Rank |
|---|---|---|
| Operating Income | $0.00M | 7/15 |
| Net Income | $0.00M | 5/13 |
| SG&A Expense | $590K | 12/12 |
| Cost of Goods Sold | $1M | 6/8 |
Dividend & Shareholder Information
| Metric | VSBC | Rank |
|---|---|---|
| Shares Outstanding | 207M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $10K | |
| Cash & Short-term Investments | $10K | |
| Total Liabilities | $5M | |
| Short-term Debt | $2M |
VSBC quarterly financials and insider trading
Vitaspring Biomedical Co. Ltd. (VSBC) industry peers
Companies classified under the same SEC industry code as Vitaspring Biomedical Co. Ltd. (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| VSBC Vitaspring Biomedical Co. Ltd. | ▼ | $7M |
| IQV Iqvia Holdings Inc. | ▼ | $43.51B |
| INCY Incyte Corp | ▼ | $21.70B |
| MEDP Medpace Holdings, Inc. | ▶ | $17.02B |
| CRL Charles River Laboratories International, Inc. | ▶ | $14.27B |
| ICLR Icon Plc | ▶ | $12.68B |
| ABSI Absci Corp | ▲ | $1.56B |
| OABI Omniab, Inc. | ▲ | $683M |
| NRC Nrc Health | ▲ | $446M |
| MXCT Maxcyte, Inc. | ▲ | $100M |
| ONMD Onemednet Corp | ▶ | $24M |
| BUDZ Weed, Inc. | ▲ | $3M |
| BIAF Bioaffinity Technologies, Inc. | ▼ | N/A |
| CBIH Cannabis Bioscience International Holdings, Inc. | ▼ | N/A |
| FOXO Foxo Technologies Inc. | ▼ | N/A |
| ISPC Ispecimen Inc. | ▼ | N/A |
Where VSBC sits on the market map
Vitaspring Biomedical Co. Ltd. (VSBC) stock news
Loading...
Vitaspring Biomedical Co. Ltd. (VSBC) stock forecast FAQ
What is the Vitaspring Biomedical Co. Ltd. (VSBC) stock forecast?
Our AI ranks Vitaspring Biomedical Co. Ltd. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Vitaspring Biomedical Co. Ltd. stock predictions?
A per-ticker accuracy statistic for VSBC is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Vitaspring Biomedical Co. Ltd. forecasts updated?
Vitaspring Biomedical Co. Ltd. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Vitaspring Biomedical Co. Ltd.'s industry peers?
16 issuers in our coverage, VSBC included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Incyte Corp (INCY), Medpace Holdings, Inc. (MEDP), Charles River Laboratories International, Inc. (CRL), Icon Plc (ICLR), Absci Corp (ABSI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.